Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma [0.03%]
在恶性胸膜间皮瘤扩大的剥脱术之前的临床决策中将Ki67（MIB-1）作为预后标记物
Robert A Belderbos,Alexander P W M Maat,Sara J Baart et al.
Robert A Belderbos et al.
Introduction: The role of surgery for early stage malignant pleural mesothelioma (MPM) remains controversial. Current expert opinion is only to treat patients surgically as part of multimodality therapy. It is still chall...
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping [0.03%]
太空行走：利用等离子细胞自由DNA基因分型进行ALK抗性的远程参与研究
Marissa N Lawrence,Rubii M Tamen,Pablo Martinez et al.
Marissa N Lawrence et al.
Introduction: Remote consent and enrollment offer a unique opportunity to provide rare cancer populations with access to clinical research. The genomic analysis of plasma cell-free DNA (cfDNA) permits remote characterizat...
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC [0.03%]
exemestane联合卡铂为基础的治疗绝经后女性晚期NSCLC的疗效研究
Patricia A Young,Diana C Márquez-Garbán,Zorawar Singh Noor et al.
Patricia A Young et al.
Introduction: Estrogen receptors (ER) (ERα, ERβ) and aromatase (key enzyme for estrogen synthesis) are expressed in most human NSCLCs. High intratumoral estrogen levels and elevated aromatase expression in NSCLC predict...
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors [0.03%]
胸内肿瘤中参与项目死亡蛋白1/项目死亡配体1轴免疫治疗试验的现状分析
Samuel A Kareff,Suraj Samtani,Mauricio Burotto et al.
Samuel A Kareff et al.
Introduction: The clinical successes seen with anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) agents have galvanized the field of immuno-oncology. We evaluated the landscape and trends in im...
Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation [0.03%]
带有种系EGFR T790M突变的肺腺癌患者的基因组进化过程
Netta Mäkinen,Meng Zhou,Meredith Bemus et al.
Netta Mäkinen et al.
Introduction: A subset of lung adenocarcinomas (ADs) has been found to have somatic activating mutations in the tyrosine kinase domain of the EGFR gene, associated with response to EGFR tyrosine kinase inhibitor therapy. ...
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung [0.03%]
纳武单抗对先前接受过治疗的肺大细胞神经内分泌癌晚期患者的疗效简介
Camille Agar,Margaux Geier,Guillaume Léveiller et al.
Camille Agar et al.
Introduction: The optimal management of large cell neuroendocrine cancer of the lung (LCNEC) is unclear, and data regarding anti-programmed cell death protein 1 (PD-1) antibodies are scarce. This study reports the clinica...
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report [0.03%]
MET 外显子 14 跳跃突变阳性肺腺癌伴有脑膜转移的患者对 Tepotinib 的 Lazarus 反应：病例报告
Taira Ninomaru,Hideaki Okada,Mika Fujishima et al.
Taira Ninomaru et al.
The spread of next-generation sequencing enables clinicians to identify rare oncogene alterations, including MET exon 14 skipping mutation, in clinical practice for NSCLC. Several tyrosine kinase inhibitors for MET exon 14 skipping mutation...
The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases [0.03%]
随着与健康相关的生活预期的减少，肺叶切除相比楔形切除的优势也在减弱
Michelle C Salazar,Maureen E Canavan,Samantha L Walters et al.
Michelle C Salazar et al.
Introduction: Patients with early-stage NSCLC typically must choose between a surgery with superior local control (lobectomy) or one that preserves lung parenchyma (wedge). Recognizing that many patients with cancer have ...
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial [0.03%]
在先前接受过基于铂类的化疗的老年晚期NSCLC患者中，S-1与多西他赛的有效性和安全性：EAST-LC试验的一个亚组分析
James Chih-Hsin Yang,Tony S K Mok,Shun Lu et al.
James Chih-Hsin Yang et al.
Introduction: Despite recent advances in NSCLC treatment, specific data on the elderly population remain limited. In this post hoc subgroup analysis of the East Asia S-1 Trial in Lung Cancer (EAST-LC) trial, we compared S...
Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria-Reducing Race Disparities [0.03%]
简报：风险预测模型与美国预防服务工作组2020年肺癌筛查资格标准草案-减少种族差异
Mary M Pasquinelli,Martin C Tammemägi,Kevin L Kovitz et al.
Mary M Pasquinelli et al.
Introduction: Eligibility criteria for lung cancer screening based solely on age and smoking history are less sensitive than validated risk prediction models. The U.S. Preventive Services Task Force (USPSTF) has proposed ...